Personalised medicine in asthma: Time for action

European Respiratory Review

Volumn 26, Issue 145, 2017, Pages

  Chung, Kian Fan ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR3; CORTICOSTEROID; INTERLEUKIN 13; ANTIASTHMATIC AGENT;

ARTICLE; ASTHMA; CLINICAL PRACTICE; DISEASE PREDISPOSITION; DISEASE SEVERITY ASSESSMENT; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; GENE EXPRESSION PROFILING; HUMAN; PATIENT MONITORING; PERSONALIZED MEDICINE; PHENOTYPE; PRACTICE GUIDELINE; PROTEIN EXPRESSION; TELEMEDICINE; TRANSCRIPTOMICS; CLINICAL DECISION MAKING; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; LUNG; MOLECULAR DIAGNOSIS; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; RISK FACTOR;

ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL DECISION-MAKING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG; MOLECULAR DIAGNOSTIC TECHNIQUES; PATIENT SELECTION; PHENOTYPE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TELEMEDICINE;

EID: 85030225189     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0064-2017     Document Type: Article

References (29)

1. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875-879.
2. Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13: 11.
3. Chung KF. New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respir Med 2013; 1: 639-652.
4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-373.
5. Lefaudeux D, De Meulder B, Loza MJ, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum-omics. J Allergy Clin Immunol 2017; 139: 1797-1807.
6. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315-323.
7. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-224.
8. Wu W, Bleecker E, Moore W, et al. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol 2014; 133: 1280-1288.
9. Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 2014; 44: 97-108.
10. Chung KF, Adcock IM. How variability in clinical phenotypes should guide research into disease mechanisms in asthma. Ann Am Thorac Soc 2013; 10: Suppl, S109-S117.
11. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-395.
12. Kuo CS, Pavlidis S, Loza M, et al. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J 2017; 49: 1602135.
13. Simpson JL, Phipps S, Baines KJ, et al. Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J 2014; 43: 1067-1076.
14. Meyers DA, Bleecker ER, Holloway JW, et al. Asthma genetics and personalised medicine. Lancet Respir Med 2014; 2: 405-415.
15. Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med 2015; 3: 849-858.
16. de Groot JC, Storm H, Amelink M, et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res 2016; 2: 00100-2015.
17. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017; 5: 390-400.
18. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: 2115-2127.
19. Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J 2017; 49: 1700634.
20. Amur S, LaVange L, Zineh I, et al. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Ther 2015; 98: 34-46.
21. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67: 199-208.
22. Gaillard EA, McNamara PS, Murray CS, et al. Blood eosinophils as a marker of likely corticosteroid response in children with preschool wheeze: time for an eosinophil guided clinical trial? Clin Exp Allergy 2015; 45: 1384-1395.
23. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
24. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198-1207.
25. Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016; 4: 549-556.
26. Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187: 804-811.
27. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107-1119.
28. Chung KF, Adcock IM. Clinical phenotypes of asthma should link up with disease mechanisms. Curr Opin Allergy Clin Immunol 2015; 15: 56-62.
29. Simpson AJ, Honkoop PJ, Kennington E, et al. Perspectives of patients and healthcare professionals on mHealth for asthma self-management. Eur Respir J 2017; 49; 1601966.